Your institution may have access to this item. Find your institution then sign in to continue.
Title
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Authors
Cohn, David E; Kim, Kenneth H; Resnick, Kimberly E; O'Malley, David M; Straughn, J Michael, Jr
Abstract
To determine whether the addition of bevacizumab to paclitaxel and carboplatin for the primary treatment of advanced ovarian cancer can be cost effective.
Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 10, p1247